First Plasmid DNA Immunotherapy for RRP Receives Accelerated FDA Approval

The U.S. FDA has granted accelerated approval to VOCERYQ, the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP). This treatment, developed by Inovio, aims to reduce the frequency of surgeries for patients with this serious condition. The manufacturer must conduct post-approval trials to confirm its clinical benefit, offering a new therapeutic approach.